Skip to main content

Table 1 Baseline characteristics of survivors and non-survivors in hospital in derivation and validation datasets

From: Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis

Characteristics

Derivation set (n = 1891)

Validation set (n = 1855)

Survivorsa

(n = 1463)

Non-survivorsb

(n = 428)

p value

Survivorsc

(n = 1410)

Non-survivorsd

(n = 445)

p value

Age (year): mean (SD)

59.3 (16.92)

67.7 (14.58)

<0.001e

59.6 (16.07)

68.3 (14.40)

<0.001e

Gender: n (%)

 Male

830 (56.93)

231 (54.10)

0.301f

786 (56.22)

266 (59.91)

0.172f

 Female

628 (43.07)

196 (45.90)

 

612 (43.78)

178 (40.09)

 

BMI (kg/m2): mean (SD)

28.5 (7.69)

27.1 (6.93)

<0.001e

28.9 (8.39)

27.1 (6.78)

<0.001e

Use of thromboprophylaxis: n (%)

 Unfractionated heparin

718 (49.08)

234 (54.67)

0.042f

696 (49.36)

225 (50.56)

0.659f

 Dalteparin

745 (50.92)

194 (45.33)

 

714 (50.64)

220 (49.44)

 

APACHE II score: mean (SD)

20.8 (7.61)

24.1 (7.59)

<0.001e

20.6 (7.59)

24.5 (7.84)

<0.001e

History of malignancy: n (%)

50 (3.43)

21 (4.92)

0.155f

47 (3.36)

32 (7.21)

<0.001f

Medical admission: n (%)

1086 (74.23)

353 (82.48)

<0.001f

1046 (74.18)

346 (77.75)

0.129f

Diagnosis of sepsis on admission: n (%)

208 (14.27)

90 (21.08)

<0.001f

177 (12.66)

74 (16.67)

0.032f

Intervention within the first 24 h on admission: n (%)

 Inotropes or vasopressors

614 (42.20)

241 (56.44)

<0.001f

579 (41.42)

243 (54.73)

<0.001f

 Invasive mechanical ventilation

1207 (82.96)

373 (87.35)

0.030f

1149 (82.19)

380 (85.59)

0.097f

 Dialysis

57 (3.92)

45 (10.54)

<0.001f

87 (6.22)

39 (8.78)

0.063f

 Acetylsalicylic acid or clopidogrel

290 (19.93)

113 (26.46)

0.004f

289 (20.49)

112 (25.23)

0.029f

 Statin

169 (11.62)

62 (14.52)

0.108f

199 (14.23)

59 (13.29)

0.617f

  1. aMedian follow-up: 18 days; interquartile range (IQR): 11–33 days
  2. bMedian survival time: 14 days; IQR 7.5–28 days
  3. cMedian follow-up: 19 days; IQR 11–37 days
  4. dMedian survival time: 15 days; IQR 7–29 days
  5. eStudent’s t test
  6. fChi-square test